Aigner K R, Gailhofer S, Brammer C
Dept. of Surgical Oncology, Asklepios Paulinen Klinik, Wiesbaden, Germany.
Gan To Kagaku Ryoho. 1998 Jan;25(1):111-4.
Fourty-five patients with progressive FIGO IIIc (36/45 pts.) and IV (9/45 pts.) ovarian cancer, who were in progression under prior cisplatin-based chemotherapy, were submitted to aortic infusion and stop flow infusion with the same drugs. 36/45 patients (80%) had four-quadrant and 9/45 patients (20%) had two-quadrant peritoneal carcinosis, 33/45 with severe ascites. Overall clinical response was 93%: 5/45 CR (11%), 21/45 PR (47%), 16/45 MR (35%). Complete resolution of ascites occurred in 9/33 patients (27%), a substantial reduction of ascites of more than 50% in 14/33 patients (43%). Median survival time was 12.5 months, median time to progression 8.6 months. Toxicity was minimal and in most patients performance and quality of life improved shortly after therapy.
45例FIGO IIIc期（36/45例）和IV期（9/45例）的晚期卵巢癌患者，在先前基于顺铂的化疗过程中出现病情进展，接受了相同药物的主动脉灌注和阻断血流灌注治疗。36/45例患者（80%）有四象限腹膜转移，9/45例患者（20%）有两象限腹膜转移，33/45例有严重腹水。总体临床缓解率为93%：5/45例完全缓解（CR，11%），21/45例部分缓解（PR，47%），16/45例疾病稳定（MR，35%）。9/33例患者（27%）腹水完全消退，14/33例患者（43%）腹水显著减少超过50%。中位生存时间为12.5个月，中位疾病进展时间为8.6个月。毒性极小，大多数患者在治疗后不久身体状况和生活质量得到改善。
